Chemomab TherapeuticsCMMB
13F holders, Q1 2025 (March 31)17holders +1
1new positions
0sold out
$1.09avg. 13F price*
At the end of Q1 2025, 17 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, up 1 from Q4 2024. 1 opened new positions and 0 sold out. The largest holders were Orbimed Advisors LLC ($1.9M), Sphera Funds Management LTD. ($981K) and Yelin Lapidot Holdings Management Ltd. ($630K).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C104
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $24K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 62,594 shares bought and 491,638 shares sold, net −429,044 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Orbimed Advisors LLC | 0.05% | No change | 1,741,273 | $1.9M |
| Sphera Funds Management LTD. | 0.24% | Reduce -25.9% | 900,428 | $981K |
| Yelin Lapidot Holdings Management Ltd. | 0.12% | Reduce -22.3% | 578,291 | $630K |
| Ikarian Capital, LLC | 0.08% | No change | 213,052 | $232K |
| Morgan Stanley | 0.00% | Add +12.2% | 117,160 | $128K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 31,241 | $34K |
| Virtu Financial LLC | 0.00% | Add +113.2% | 30,803 | $34K |
| Boothbay Fund Management, LLC | 0.00% | No change | 26,189 | $29K |
| Rhumbline Advisers | 0.00% | Add +0.2% | 23,849 | $26K |
| Two Sigma Securities, LLC | 0.00% | New | 22,104 | $24K |
| XTX Topco Ltd | 0.00% | Reduce -46.8% | 13,274 | $14K |
| GAMMA Investing LLC | 0.00% | Add +116.3% | 11,028 | $12K |
| Wetzel Investment Advisors, Inc. | 0.01% | Add +10.0% | 11,000 | $12K |
| BNP Paribas Financial Markets | 0.00% | Add +61.5% | 10,500 | $11K |
| UBS Group AG | 0.00% | Add +82.1% | 883 | $962 |
| Moser Wealth Advisors, LLC | 0.00% | No change | 500 | $545 |
| SBI Securities Co., Ltd. | 0.00% | Add +4.0% | 104 | $113 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.